🔍 See what insiders are buying — free 7-day trial, no credit card required.
Get started →
MRK
NYSE
🇺🇸 US
Merck & Co., Inc.
Pharmaceuticals
21Score
DipBuster Score™
$126.26
+$1.86 (+1.5%)
Live price · Source: Yahoo
52-Week Position
$76.66
90% of range
$131.74
Beta
0.205
Low vol
Dividend
—
no income
Mkt Cap
N/A
total value
Mkt CapN/A
P/EN/A
DividendNone
Beta0.205
52W High$131.74
52W Low$76.66
DipBuster Brief
Key signals at a glance
Zone: Sell / Avoid
Bearish
Near 52-Week High — Asymmetric Risk
At 90% of its annual range the stock is close to its peak. New buyers face limited upside and meaningful downside if sentiment shifts.
Neutral
Earnings Data Unavailable
P/E ratio could not be determined — this is common for early-stage, loss-making, or recently-listed companies.
Valuation
P/E Ratio—
Mkt CapN/A
52W Position90% of range
EV/EBITDA—
Cash Flow
FCF Yield—
FCF / Share
Op. Cash Flow—
Margins
Gross Margin—
Op. Margin—
Net Margin—
Balance Sheet
Cash—
Total Debt—
Net Cash—
Dividend
Yield—
Annual / shNone
Beta0.205
🔒
FCF, margins & balance sheet data are hidden — create a free account to see them.
🕵️ Insiders
📊 Valuation
💰 Dividends
📰 News
🤖 AI Analysis
Recent director dealings and insider transactions at Merck & Co., Inc. (MRK), from SEC Form 4 filings. Open-market buys by directors spending their own money are one of the strongest signals in investing.
| Date | Insider | Type | Shares |
|---|---|---|---|
| 2026-06-30 | Seidman Christine E | BUY | 63 |
| 2026-06-30 | Karsanbhai Surendralal Lanca | BUY | 126 |
| 2026-06-30 | Coe Mary Ellen | BUY | 233 |
| 2026-05-29 | Mayo Stephen | BUY | 1,853 |
| 2026-05-29 | Seidman Christine E | BUY | 1,853 |
| 2026-05-29 | Karsanbhai Surendralal Lanca | BUY | 1,853 |
| 2026-05-29 | Coe Mary Ellen | BUY | 1,853 |
| 2026-05-29 | Rothman Paul | BUY | 1,853 |
| 2026-05-29 | Warden Kathy J | BUY | 1,853 |
| 2026-05-29 | Thulin Inge G | BUY | 1,853 |
Valuation
P/E RatioN/A
Market CapN/A
Beta0.205
Dividend/yrNone
52W High$131.74
52W Low$76.66
52-Week Range
$76.66Now$131.74
90% through annual range
From 52W High−4.2%
From 52W Low+64.7%
📖 Plain English Summary
Merck & Co., Inc. is at 90% of its 52-week range. Beta 0.205 — tends to move less than the market.
🏦 Analyst Price Target
Loading…
🎯 Analyst Revenue & EPS Estimates
Loading estimates…
🔄 Peer Comparison
Loading peers…
Loading dividend data…
Latest news for MRK
🟢 Bullish
⬜ Neutral
🔴 Bearish
🤖
DipBuster AI Analysis — MRK
Heuristic · balance sheet, insider filings, price data, academic research
Merck & Co., Inc. — DipBuster Score 21/100
Graham value assessment, NCAV analysis, price zones...
Insider signals, cluster detection, risk factors...
Track Merck & Co., Inc. free
Add MRK to a watchlist, set insider-buy and price alerts, and get the full financial picture — free account, no card.
Sponsored · FCA Regulated Broker
Trading 212
Commission-free investing. ISA and GIA available. FCA regulated.
Free share worth up to £100 when you sign up
Capital at risk. Your investments can go down as well as up. Disclaimer
DipBuster Score™ Breakdown
Value & P/E
0/30
Dip Position
4/25
Momentum & Volume
12/25
Quality & Size
5/10
Insider Activity
0/10
🎯 Dip Buyer Signal
0
/100 · NEUTRAL
dip depth
0/25
oversold rsi
0/25
mean reversion
0/15
insider zone
0/25
capitulation
0/10
Technical signal only. Not financial advice.
Quick Take
⚪
Not a Dip
DipBuster Score: 21/100
📊
Run a full check in the AI analysis tab for a deeper look.
Company Profile
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medici…
Sector
Pharmaceuticals
Market
🇺🇸 US
CEO
Robert Davis
Staff
75,000 employees
Website